Please provide your email address to receive an email when new articles are posted on . Fewer than 2% of patients who received long-acting injectable antipsychotics were readmitted vs. 8.3% of those ...

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy ...

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...

Second-generation antipsychotic drugs are widely used for treatment of psychotic disorders, but only risperidone comes in a depot formulation. Depot medications are an important component of the ...

—Learn how a group of providers with the Indian Health Service searched for ways to overcome barriers to medication adherence among people with schizophrenia. At a rural Indian Health Service Hospital ...

2025 MAR 04 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News-- Researchers detail new data in Managed Care. According to news originating from Athens, Georgia, by NewsRx ...

A new study analyzing Medicaid databases from 2017 to 2021 has uncovered significant differences in how long-acting injectable (LAI) antipsychotic medications are prescribed to older adults across ...

More than 92% of schizophrenia patients taking Olanzapine LAI in the Phase 3 SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication 1.

One of the most important goals in the treatment of people with schizophrenia is preventing relapses, which often lead to periods of hospitalization. Discontinuing Medication Can Cause Relapse in ...

—These retrospective study findings may have implications for providers and policy makers as they work to find treatments that not only are effective but have minimal side effects. Despite the crucial ...